RU2016143155A3 - - Google Patents

Download PDF

Info

Publication number
RU2016143155A3
RU2016143155A3 RU2016143155A RU2016143155A RU2016143155A3 RU 2016143155 A3 RU2016143155 A3 RU 2016143155A3 RU 2016143155 A RU2016143155 A RU 2016143155A RU 2016143155 A RU2016143155 A RU 2016143155A RU 2016143155 A3 RU2016143155 A3 RU 2016143155A3
Authority
RU
Russia
Application number
RU2016143155A
Other languages
Russian (ru)
Other versions
RU2701341C2 (ru
RU2016143155A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50486692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016143155(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2016143155A publication Critical patent/RU2016143155A/ru
Publication of RU2016143155A3 publication Critical patent/RU2016143155A3/ru
Application granted granted Critical
Publication of RU2701341C2 publication Critical patent/RU2701341C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016143155A 2014-04-03 2015-04-02 Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака RU2701341C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201470171 2014-04-03
DKPA201470171 2014-04-03
PCT/EP2015/057331 WO2015150526A2 (en) 2014-04-03 2015-04-02 Cd33 specific chimeric antigen receptors for cancer immunotherapy

Publications (3)

Publication Number Publication Date
RU2016143155A RU2016143155A (ru) 2018-05-04
RU2016143155A3 true RU2016143155A3 (enExample) 2018-10-23
RU2701341C2 RU2701341C2 (ru) 2019-09-25

Family

ID=50486692

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016143155A RU2701341C2 (ru) 2014-04-03 2015-04-02 Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака

Country Status (13)

Country Link
US (3) US9944702B2 (enExample)
EP (1) EP3126390B1 (enExample)
JP (1) JP6673848B2 (enExample)
KR (1) KR102170533B1 (enExample)
CN (1) CN106795221B (enExample)
AU (1) AU2015239069B2 (enExample)
CA (1) CA2944528C (enExample)
DK (1) DK3126390T3 (enExample)
ES (1) ES2765710T3 (enExample)
IL (1) IL247917B (enExample)
MX (1) MX370788B (enExample)
RU (1) RU2701341C2 (enExample)
WO (1) WO2015150526A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US9944702B2 (en) * 2014-04-03 2018-04-17 Cellectis CD33 specific chimeric antigen receptors for cancer immunotherapy
JP6698546B2 (ja) * 2014-04-14 2020-05-27 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
MX390943B (es) 2014-07-21 2025-03-21 Novartis Ag Receptores de antígeno quimérico cd33 y usos de los mismos.
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
EP4265633A3 (en) * 2015-10-16 2024-01-24 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
DK3368571T5 (da) * 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
CN109715207B (zh) * 2016-03-29 2023-03-31 南加利福尼亚大学 靶向癌症的嵌合抗原受体
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
EP3468994A1 (en) 2016-06-08 2019-04-17 Intrexon Corporation Cd33 specific chimeric antigen receptors
JP2020513248A (ja) 2016-10-19 2020-05-14 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響による親和性細胞抽出
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
WO2018160768A1 (en) 2017-02-28 2018-09-07 Vor Biopharma, Inc. Compositions and methods for inhibition lineage specific proteins
JP7137896B2 (ja) 2017-03-24 2022-09-15 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3615076A4 (en) * 2017-04-24 2021-06-02 Memorial Sloan Kettering Cancer Center ANTI-BODY AGENTS ANTI-CD33
WO2018213467A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
CA3070409A1 (en) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting cd33-expressing cancers
US12065498B2 (en) 2017-09-29 2024-08-20 Cell Design Labs, Inc. Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
WO2019084234A1 (en) * 2017-10-26 2019-05-02 St. Jude Childen's Research Hospital, Inc. METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
GB201719646D0 (en) * 2017-11-27 2018-01-10 Bivictrix Therapeutics Ltd Therapy
WO2019113041A1 (en) * 2017-12-04 2019-06-13 Actinum Pharmaceuticals, Inc. Methods for treatment of patients with myelodyplastic syndromes
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
CN108047333B (zh) * 2018-01-15 2021-05-25 浙江阿思科力生物科技有限公司 以cd33为靶点的特异性抗体、car-nk细胞及其制备和应用
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
KR20200131867A (ko) * 2018-03-14 2020-11-24 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항-cd33 키메라 항원 수용체 및 이의 용도
EP3768700A1 (en) 2018-03-23 2021-01-27 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) * 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
CN110551741A (zh) * 2018-06-01 2019-12-10 上海恒润达生生物科技有限公司 靶向cd33的嵌合抗原受体及其用途
SG11202011895VA (en) 2018-06-04 2020-12-30 Intrexon Corp Muc16 specific chimeric antigen receptors and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019246563A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
MX2021002415A (es) 2018-08-28 2021-09-21 Vor Biopharma Inc Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas.
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US12398402B2 (en) 2018-09-12 2025-08-26 Fred Hutchinson Cancer Center Reducing CD33 expression to selectively protect therapeutic cells
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
EP4578507A3 (en) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
CN113227141A (zh) * 2018-11-07 2021-08-06 克里斯珀医疗股份公司 抗cd33免疫细胞癌症疗法
WO2020123947A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020150478A1 (en) * 2019-01-16 2020-07-23 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
WO2020219425A1 (en) * 2019-04-25 2020-10-29 Seattle Children's Hospital (dba Seattle Children's Research Institute) Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
KR20220016083A (ko) 2019-04-30 2022-02-08 센티 바이오사이언시스, 인코포레이티드 키메라 수용체 및 이의 사용 방법
MA55907A (fr) * 2019-05-08 2022-03-16 2Seventy Bio Inc Immunothérapies ciblées sur cd33
CN114040978B (zh) * 2019-05-31 2025-10-17 希望之城公司 用于治疗cd33阳性恶性肿瘤的经cd33靶向性嵌合抗原受体修饰的t细胞
WO2020257823A2 (en) 2019-06-21 2020-12-24 Kite Pharma, Inc. TGF-β RECEPTORS AND METHODS OF USE
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
CN115348973A (zh) * 2020-03-31 2022-11-15 弗莱德哈钦森癌症中心 靶向cd33的嵌合抗原受体
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
IL303656A (en) 2020-12-17 2023-08-01 Hoffmann La Roche Anti-hla-g antibodies and use thereof
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022266075A1 (en) 2021-06-14 2022-12-22 Caribou Biosciences, Inc. Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
CN113527435B (zh) * 2021-07-14 2022-06-07 呈诺再生医学科技(珠海横琴新区)有限公司 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用
GB202204386D0 (en) * 2022-03-28 2022-05-11 Cambridge Entpr Ltd Engineered immune cell platform
WO2025008108A1 (en) 2023-07-06 2025-01-09 Miltenyi Biotec B.V. & Co. KG Immune cell expressing chimeric antigen receptor and transgenic t cell receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229208A1 (en) * 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
PT659439E (pt) * 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
AU2003285878B2 (en) 2002-11-07 2011-04-28 Immunogen, Inc. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
ES2717629T3 (es) * 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9447194B2 (en) * 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2013176915A1 (en) 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US9944702B2 (en) * 2014-04-03 2018-04-17 Cellectis CD33 specific chimeric antigen receptors for cancer immunotherapy
JP6698546B2 (ja) * 2014-04-14 2020-05-27 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体

Also Published As

Publication number Publication date
EP3126390A2 (en) 2017-02-08
JP6673848B2 (ja) 2020-03-25
MX370788B (es) 2020-01-06
IL247917B (en) 2020-11-30
AU2015239069B2 (en) 2020-02-20
CA2944528C (en) 2021-08-10
US20190002561A1 (en) 2019-01-03
CN106795221B (zh) 2022-06-07
DK3126390T3 (da) 2020-01-20
MX2016012855A (es) 2016-12-12
CN106795221A (zh) 2017-05-31
US20240182565A1 (en) 2024-06-06
RU2701341C2 (ru) 2019-09-25
AU2015239069A1 (en) 2016-10-06
KR102170533B1 (ko) 2020-10-27
US20170145094A1 (en) 2017-05-25
BR112016022369A2 (pt) 2017-10-10
IL247917A0 (en) 2016-11-30
RU2016143155A (ru) 2018-05-04
US9944702B2 (en) 2018-04-17
WO2015150526A2 (en) 2015-10-08
JP2017515460A (ja) 2017-06-15
EP3126390B1 (en) 2019-10-16
KR20170002412A (ko) 2017-01-06
CA2944528A1 (en) 2015-10-08
WO2015150526A3 (en) 2015-11-26
ES2765710T3 (es) 2020-06-10

Similar Documents

Publication Publication Date Title
BR112016017659A2 (enExample)
BR112016018389A2 (enExample)
BR112016016536A2 (enExample)
BR112016015813A2 (enExample)
BR112016017303A2 (enExample)
BR112016017031A2 (enExample)
BR112016015845A2 (enExample)
BR112016018468A2 (enExample)
BR112016016008A2 (enExample)
BR112016016933A2 (enExample)
BR112016017226A2 (enExample)
BR112016003131A2 (enExample)
BR112016016193A2 (enExample)
BR112016017306A2 (enExample)
BR112016015256A2 (enExample)
BR112016018552A2 (enExample)
AP2016009666A0 (enExample)
BR112016017960A2 (enExample)
BR112016018632A2 (enExample)
BR112016017927A2 (enExample)
BR112016016944A2 (enExample)
BR112016015911A2 (enExample)
BR112016018603A2 (enExample)
BR112016018728A2 (enExample)
BR112016017130A2 (enExample)